XML 15 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
Intangible assets
9 Months Ended
Sep. 30, 2022
Intangible Assets  
Intangible assets

 

  4. Intangible assets

 

                               
      Product development in progress       Intellectual property and patents registration       Software       Total  
2022     €’000       €’000       €’000       €’000  
Cost                
At January 1, 2022     1,918       1,911       23       3,852  
Additions – other*     1,404                41       1,445  
At September 30, 2022     3,322       1,911       64       5,297  
                                 
Amortisation                                
At January 1, 2022                       (5 )     (5 )
Amortisation charge                       (11 )     (11 )
At September 30, 2022                       (16 )     (16 )
                                 
Net book value                                
At September 30, 2022     3,322       1,911       48       5,281  
                                 
2021                                
Cost                                
At January 1, 2021     288       1,911       4       2,203  
Additions – other*     1,630                19       1,649  
At December 31, 2021     1,918       1,911       23       3,852  
                                 
Amortisation                                
At January 1, 2021                                    
Amortisation charge                       (5 )     (5 )
At December 31, 2021                       (5 )     (5 )
                                 
Net book value                                
At December 31, 2021     1,918       1,911       18       3,847  

 

* The additions relate to materials acquired during the period for the purpose of developing our HEVO technology.

 

Intellectual property at September 30, 2022 and December 31, 2021 of €1.9 million and €1.9 million respectively, and product development costs of €3.3 million and €1.9 million respectively, are considered to be of indefinite life and accordingly are not amortized. In line with the Group’s accounting policy, development expenditure is measured at cost less accumulated amortisation and any accumulated impairment losses, unless the product development costs are still being used in product development in which case it is considered indefinite useful life. During the fourth quarter of 2022, the Group began to amortise a significant portion of the product development costs on the basis that they were no longer considered to be used in product development. These items are being amortized over useful lives of between 3 and 5 years.

 

The Group considers that there have been no indicators of impairment during the period. The annual impairment analysis will be performed as at December 31, 2022.